Executives at drug company Actavis knew they had to move fast to avoid a plunge in sales of their top-selling drug, Namenda, a treatment for Alzheimer’s disease which would lose patent protection in July. When that happened, generic knockoffs would flood the market and doctors and pharmacists could switch patients to the lower-cost equivalents. With […]
At the J.P. Morgan Healthcare Conference this week some of the biggest names in healthcare gathered to discuss the state of the biopharmaceuticals sector. Amidst all of the commotion, some executives took a moment to tell CNBC‘s Meg Tirrell which CEO (in any industry) they’d most like to trade places with if given the chance. […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Generic pharmaceutical manufacturer Actavis Group’s U.S. subsidiary has agreed to partner with clinical stage specialty pharmaceutical company QRxPharma in a licensing deal to commercialize acute pain medication MoxDuo IR in the United States, in a move that will reshape the Morristown, New Jersey company’s analgesic sales force for branded products. Under the terms of the […]